The body produces less GLP-1, and the remaining GLP-1 is rapidly degraded by the enzyme DPP-4
Phase 3 trials of CagriSema demonstrated: 15.6% body weight loss with the combination versus 8.1% with semaglutide alone Superior glycemic control compared to either component individually Manageable side effect profile with proper dose titration Regulatory submissions completed in 2024 for obesity treatment [6] Since retatrutide includes GLP-1 receptor activation (similar to semaglutide) plus additional GIP and glucagon receptor effects, the theoretical cagrilintide blend with retatrutide could potentially exceed even the impressive CagriSema results
References Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrom SZ, Davies MJ, Hovingh GK, Kitzman DW, Moller DV, Verma S, et al
Salz nach Anspruch 1 oder 2, wobei Xaa Ala, bAla, Leu, Ile, Gly, Val, Nle oder Nva ist, Yaa Lys, Arg, Orn oder His ist und Zaa Glu, Asp, Aad oder Amp ist